受强制性开放获取政策约束的文章 - Xiaocen Li了解详情
无法在其他位置公开访问的文章：4 篇
Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with “lock-in” function
Y Zhao, B Qu, X Wu, X Li, Q Liu, X Jin, L Guo, L Hai, Y Wu
European journal of medicinal chemistry 82, 314-323, 2014
强制性开放获取政策： 国家自然科学基金委员会
Design, synthesis and evaluation of dual-targeting prodrug co-modified by organic amine and L-ascorbic acid for CNS delivery
S Qiu, Y Zhao, S Liu, X Li, L Guo, L Hai, Y Wu
Letters in Drug Design & Discovery 14 (9), 1065-1072, 2017
强制性开放获取政策： 国家自然科学基金委员会
A new and efficient method for the synthesis of Ulipristal acetate
X Cheng, X Li, Y Duan, Y Yu, L Hai, Y Wu
Steroids 84, 78-83, 2014
强制性开放获取政策： 国家自然科学基金委员会
Peptide Therapeutics: Oncology
R Liu, X Li, TC Shih, JS Lee, KS Lam
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：17 篇
Combinatorial chemistry in drug discovery
R Liu, X Li, KS Lam
Current opinion in chemical biology 38, 117-126, 2017
强制性开放获取政策： US National Institutes of Health
Tumor-targeting peptides from combinatorial libraries
R Liu, X Li, W Xiao, KS Lam
Advanced drug delivery reviews 110, 13-37, 2017
强制性开放获取政策： US National Institutes of Health
Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion
TC Shih, R Liu, CT Wu, X Li, W Xiao, X Deng, S Kiss, T Wang, XJ Chen, ...
Clinical Cancer Research 24 (17), 4319-4331, 2018
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy
X Xue, Y Huang, X Wang, Z Wang, RP Carney, X Li, Y Yuan, Y He, T Lin, ...
Biomaterials 161, 203-215, 2018
强制性开放获取政策： US National Institutes of Health
Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model
Q Long, T Lin, Y Huang, X Li, A Ma, H Zhang, R Carney, S Airhart, ...
Nanomedicine: Nanotechnology, Biology and Medicine 14 (3), 789-799, 2018
强制性开放获取政策： US Department of Defense, US National Institutes of Health, US Department of …
Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors
TC Shih, Y Fan, S Kiss, X Li, XN Deng, R Liu, XJ Chen, R Carney, A Chen, ...
Neuro-oncology 21 (11), 1389-1400, 2019
强制性开放获取政策： US National Institutes of Health
Selectin-targeting glycosaminoglycan-peptide conjugate limits neutrophil-mediated cardiac reperfusion injury
T Dehghani, PN Thai, H Sodhi, L Ren, P Sirish, CE Nader, V Timofeyev, ...
Cardiovascular Research 118 (1), 267-281, 2022
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs, State …
Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate non-small-cell Lung Cancers In Vivo
X Wang, L Zhang, X Li, D Kong, X Hu, X Ding, J Yang, M Zhao, Y He, ...
Nanomedicine 13 (10), 1107-1120, 2018
强制性开放获取政策： US National Institutes of Health
Mechanical Load Regulates Excitation-Ca2+ Signaling-Contraction in Cardiomyocyte
R Shimkunas, B Hegyi, Z Jian, JA Shaw, MA Kazemi-Lari, D Mitra, ...
Circulation research 128 (6), 772-774, 2021
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs …
A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer
X Wang, D Kong, T Lin, X Li, Y Izumiya, X Ding, L Zhang, X Hu, J Yang, ...
Acta Pharmacologica Sinica 38 (6), 931-942, 2017
强制性开放获取政策： US National Institutes of Health
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically
X Wang, X Ding, X Li, Y He, D Kong, L Zhang, X Hu, J Yang, M Zhao, ...
Nanomedicine: Nanotechnology, Biology and Medicine 14 (7), 2103-2114, 2018
强制性开放获取政策： US Department of Defense, US National Institutes of Health
Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes
G Bharadwaj, V Nhan, SC Yang, X Li, A Narayanan, AC Macarenco, Y Shi, ...
Nanomedicine 12 (10), 1153-1164, 2017
强制性开放获取政策： US National Institutes of Health
Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors
Y Wang, Y Li, J Cao, Q Meng, X Li, Y Zhang, KS Lam, A Hong, R Liu, ...
Biomedicines 9 (8), 849, 2021
强制性开放获取政策： US National Institutes of Health
Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration‐resistant prostate cancer
Y Huang, X Xue, X Li, B Jia, CX Pan, Y Li, TY Lin
Advanced therapeutics 3 (10), 2000075, 2020
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2
Y Zhang, M Ouyang, H Wang, B Zhang, W Guang, R Liu, X Li, TC Shih, ...
MedComm 1 (3), 362-375, 2020
强制性开放获取政策： 国家自然科学基金委员会
One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer
F Yang, W Xiao, Y Liu, R Liu, R Kramer, X Li, Y Ajena, CM Baehr, ...
Oncotarget 10 (52), 5468, 2019
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定